Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.
Frequently asked questions
What sector does Klaria Pharma Holding AB (KLAR) operate in?
Klaria Pharma Holding AB belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Klaria Pharma Holding AB (KLAR) current stock price?
As of the latest data, Klaria Pharma Holding AB stock price is SEK 0.59, with a previous close of SEK 0.59. Klaria Pharma Holding AB gained SEK 0.00 in the last trading session, representing a 0.17% increase.
What is Klaria Pharma Holding AB (KLAR) current market capitalization?
Klaria Pharma Holding AB market cap is approximately 145.62 million.
What is Klaria Pharma Holding AB (KLAR) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.19.
What is Klaria Pharma Holding AB (KLAR) EBITDA?
Klaria Pharma Holding AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.14 million.
Does Klaria Pharma Holding AB (KLAR) pay dividends?
No. Klaria Pharma Holding AB does not pay a dividend.
What is Klaria Pharma Holding AB (KLAR) beta (volatility) score?
Klaria Pharma Holding AB has a beta of 1.194, meaning its volatility is roughly in line with the market.
